Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
Becton, Dickinson and Company (NYSE: BDX) commenced tender offers to purchase up to $1,600,000,000 aggregate purchase price of specified outstanding senior notes across multiple series.
Key dates: Early Tender Date Feb 24, 2026, Reference pricing Feb 25, 2026, Expiration Mar 11, 2026, anticipated settlement Mar 13, 2026 (early settlement possible Feb 27, 2026). Early tender payments are $30 per $1,000 for eligible tenders. Offer SubCaps include $1,000,000,000 for 4.669% 2047 and $450,000,000 for one 2044 series. Acceptance priority levels and fixed spreads per series determine allocation and Total Consideration.
BD (NYSE: BDX) completed the spin-off and combination of its Biosciences & Diagnostic Solutions business with Waters Corporation (NYSE: WAT) on Feb 9, 2026. BD received $4.0 billion in cash and shareholders received ~0.135 WAT shares per BDX share, with cash for fractions.
As of closing BD shareholders held 39.2% of the combined company (fully diluted). Based on WAT's Feb 6, 2026 close, the business was valued at $18.8 billion. BD expects to use $2.0 billion for an accelerated share repurchase and $2.0 billion to repay debt. Claire M. Fraser joined the Waters board and stepped down from the BD board.
Waters (NYSE: WAT) has completed its combination with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader organized into four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. The transaction used a Reverse Morris Trust, and post-close ownership is Waters 60.8% and BD shareholders 39.2% on a fully diluted basis. Claire M. Fraser, Ph.D., joined the Waters Board, expanding it to 11 members. Barclays advised Waters; Kirkland & Ellis served as lead counsel.
BD (NYSE: BDX) reported Q1 FY2026 revenue of $5.25B, up 1.6% reported (0.4% FXN), and reported diluted EPS $1.34 (+28.8%); adjusted diluted EPS was $2.91 (down 15.2%).
The company expects the Biosciences and Diagnostic Solutions combination with Waters to close Feb 9, 2026, and affirmed full-year New BD guidance: low single-digit revenue growth and adjusted diluted EPS of $12.35–$12.65.
BD (NYSE: BDX) and Envetec completed a joint feasibility pilot demonstrating closed-loop recycling of polystyrene Petri dishes into new manufacturing feedstock.
The study processed plated media as post-industrial material through Envetec's GENERATIONS chemical disinfection to produce clean polymer flakes, extruded into pellets and molded into Petri dish prototypes.
BD (NYSE: BDX) declared a quarterly cash dividend of $1.05 per common share, payable March 31, 2026, to holders of record on March 10, 2026, equal to an indicated annual dividend of $4.20 per share. The company has repurchased $250 million of BD stock to date in fiscal 2026. The board also authorized repurchases of up to 10 million additional shares of common stock, to be executed via open market purchases, privately negotiated transactions or other methods. Management will determine the timing, manner, number and value of repurchases at its discretion and subject to market, economic and business considerations.
BD (NYSE: BDX) will host an audio webcast at 8:00 a.m. ET on Monday, February 9, 2026 to discuss financial results for its first quarter of fiscal 2026 (period ended December 31, 2025) and to provide an update on operations and strategy. Prior to the call, the company will issue a news release and presentation materials including summary financial information.
The live audio webcast and subsequent replay will be available at www.bd.com/investors.
BD (NYSE: BDX) set Feb 5, 2026 as the record date for the spin-off of its Biosciences & Diagnostic Solutions business and expects to combine the spun-off unit with Waters (NYSE: WAT) via a Reverse Morris Trust on Feb 9, 2026, subject to customary closing conditions.
Under the terms, BD will receive $4 billion cash, and BD shareholders will receive Waters common stock representing 39.2% of the combined company on a fully diluted basis; Waters shareholders will own 60.8%.
Shares will trade with due bills starting Feb 5 and trade ex-distribution after closing; BD received a favorable IRS private letter ruling.
Waters (NYSE: WAT) shareholders approved issuing Waters common stock to shareholders of Becton, Dickinson and Company (NYSE: BDX) for the proposed combination of BD's Biosciences & Diagnostic Solutions business with Waters, with preliminary voting showing ~99% support.
Waters and BD received all required regulatory approvals and BD obtained a favorable IRS Private Letter Ruling on U.S. federal tax matters. The transaction is expected to close on February 9, 2026, subject to customary closing conditions. Waters will release Q4 2025 results and hold a conference call and webcast on February 9, 2026 at 8:30 a.m. ET; a replay will be available through at least March 9, 2026.
BD (NYSE: BDX) announced the global commercial release of BD Research Cloud 7.0 on January 23, 2026, introducing BD Horizon Panel Maker, an AI-powered tool for automated panel design to support immunology and cancer research.
The cloud-based platform supports collaboration, workflow streamlining and lab operations management, and the new AI tool generates optimized panel recommendations within seconds from custom inputs or curated validated databases. The release highlights integrated visualization features (comparison tables and complexity scores) and explicit support for imaging and spectral panel design with BD FACSDiscover instruments. BD Research Cloud 7.0 is commercially available at bdresearchcloud.com.